Skip to content

Comparision of various drugs used inknee osteoarthritis

Comparative study of outcomes with adjunct use of disease modifying agents in management of knee osteoarthritis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/02/006587
Enrollment
217
Registered
2016-02-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Known as well as newly diagnosed cases of primary knee osteoarthritis

Interventions

Intervention1: S-adenosyl methionine, Diacerin, Hyaluronic acid, Glucosamine-chondroitin sulfate.: Drug Regimens: The patients were prescribed various regimens of therapies entirely at discretion of

Sponsors

Institute of Medical Sciences Banaras Hindu University Varanasi Uttar Pradesh India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria: The patients with radiographic evidence of suffering grade I, II and grade III Osteoarthritis. The patients having mild to moderate grade of hypertension controlled with therapies as well as those with diabetes well controlled with therapies and suffering from osteoarthritis were also included.

Exclusion criteria

Exclusion criteria: 1.Patients suffering from severe grades of hypertension and diabetes mellitus requiring more than oral hypoglycemic therapies were excluded. 2.Untreated or poorly controlled diabetics and hypertensives were excluded. 3.Patients suffering from any other major systemic disease or active infection were excluded. 4.Patients with H/O trauma to knee in past before or after the onset of osteoarthritic symptoms were excluded. 5.Patients with more advanced (radiological grade IV) OA were excluded. 6.Patients developing any illness causing restriction of routine for one day or more as also those needing more than 3 days course of therapy for emergent illness were excluded. 7.Occasional use of single or two doses of medications up-to two instances during the 12 weeks observational period were allowed. 8.No case of pregnancy or H/O any surgery in last 3 years was included. 9.Patients non-compliant to therapy at more than two recalled occasions during any 2 weeks in treatment course were excluded.

Design outcomes

Primary

MeasureTime frame
Knee injury and osteoarthritis outcome score (KOOS score)Timepoint: At first visit and at the end of 3 months

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactDr Prashant Chaudhary
blp53@rediffmai.com07030409333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026